Aude-Anaïs Olijnik

A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.

The paper identifies chromothripsis-induced amplification of DYRK1A in blast phase MPN as a driver of aggressive disease and a potential therapeutic target.

This study models erythropoiesis in CDA-I by analyzing patient-derived erythroblasts, identifying abnormalities in DNA accessibility, proliferation, and enucleation, with genotype-phenotype correlations.